$40.25 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Inhibrx

Inhibrx Inc. is a clinical-stage biotechnology company. The Company is focused on developing biologic therapeutics for people with life-threatening conditions. It has a pipeline of novel biologic therapeutic candidates, developed using its single domain antibody (sdAb) platform. Its pipeline includes INBRX-109, INBRX-106, INBRX-105 and INBRX-101. INBRX-109 is a tetravalent death receptor 5 (DR5) agonist being evaluated in patients diagnosed with chondrosarcoma and mesothelioma cancers. INBRX-106 is a hexavalent OX40 agonist being investigated in patients with locally advanced or metastatic solid tumors. INBRX-105 is a precisely engineered tetravalent sdAb based therapeutic candidate, acting both as an antagonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB. INBRX-101 is a precisely engineered recombinant human AAT-Fc fusion protein therapeutic candidate, in development for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).

Stock Analysis

last close $40.25
1-mo return -12.5%
3-mo return 39.1%
avg daily vol. 124.47T
52-week high 50.97
52-week low 14.27
market cap. $1.5B
forward pe -
annual div. -
roe -130.5%
ltg forecast -
dividend yield -
annual rev. $7M
inst own. 54.5%

Subscribe now for daily local and international financial news